ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025
Use of Alternative Calcium Gluconate in Sodium Chloride Co-Infused With Parenteral Nutrition for Neonates and Infants During National Shortage.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging the Gap in the Clinical Application of Advanced Parenteral Nutrition Formulations: From Efficacy to Real-World Challenges.Advances in nutrition (Bethesda, Md.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe coronavirus pandemic led to many supply chain shortages including parenteral nutrition (PN) components, and for our institution, a critical shortage of calcium gluconate vials. Our institution switched to an alternative product, calcium gluconate in sodium chloride (Ca-gluconate-in-NaCl), and owing to lack of specific gravity data, it could not be placed as an additive in our compounder. Instead, it had to be used as a continuous infusion, co-infused with PN. The purpose of this study was to determine if the alternative product led to significant electrolyte abnormalities affecting calcium homeostasis in patients requiring PN.
methodsThis was a retrospective review of the electronic health record for all infants aged 0 days to 12 months from March 1, 2022, through May 31, 2022, who received PN and a continuous Ca-gluconate-in-NaCl infusion at our institution. Associations between dosing and adverse events were explored with ordinal and logistic regression.
resultsA total of 39 patients were included in our study. Ca-gluconate-in-NaCl was provided with PN for a median of 7 days. Hypocalcemia occurred in 16 of 39 (41%) study infants. Seven patients experienced mild hypocalcemia (8-8.5 mg/dL; p = 0.875), 7 experienced moderate hypocalcemia (7-7.9 mg/dL; p = 0.339), and 2 experienced severe hypocalcemia (<7 mg/dL; p = 0.214). One patient who experienced severe total serum hypocalcemia also experienced hypocalcemia as defined by ionized calcium concentrations (<1.1 mmol/L; p = 0.344).
conclusionsCa-gluconate-in-NaCl infused via Y-site with PN could be a viable alternative during shortage of calcium gluconate vials for at least 7 days in infants requiring PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.